Ficha personal - Francisco Javier Salvador Bofill


Francisco Javier Salvador Bofill
Email: Solicitar correo
Perfil en ORCID: 0000-0002-8817-5299

Grupo de Investigación: CTS-629 Oncología Molecular y Nuevas Terapias
Departamento/Unidad: Medicina
Situación profesional: Asociado (Concierto Inst. Sanit.)

Participa en los siguientes proyectos/ayudas en la US:

  • Proyectos:
    • Marcadores de cáncer stem cells en carcinoma microcítico de pulmón: valoración pronóstica y uso como dianas específicas para el desarrollo de terapias avanzadas mediante nanotransportadores dirigidos (PI-0051-2013 - Investigador)

  • Ayudas:
    • Incentivo al Grupo de Investigación CTS-657 (2011/CTS-657 - Investigador)

Cobertura de la base de datos de proyectos, véase aqui


Publicaciones:

Libros
Salvador Bofill, Francisco Javier:
Tratamiento anti-HER 2 actualización. 2012. ISBN 978-84-7885-564-3

Otra participación en Libros
Virizuela Echaburu, Juan Antonio (Miembro del Comite Cientifico), Fernandez Lopez,Auxiliadora (Miembro del Comite Cientifico), Bayo Lozano, Eloísa (Miembro del Comite Cientifico), Jimenez Orozco, Encarnacion (Impresor/a), Alonso Redondo, Enrique (Miembro del Comite Cientifico), et. al.:
Actualizacion del Manual de Competencias del Medico Especialista en Oncologia Medica. Agencia de Calidad Sanitaria de Andalucia. 2010. ISBN 978-84-92466-59-7

Virizuela Echaburu, Juan Antonio (Miembro del Comite Cientifico), Palacios Eito, Amalia (Miembro del Comite Cientifico), Fernandez Lopez,Auxiliadora (Miembro del Comite Cientifico), Bayo Lozano, Eloísa (Miembro del Comite Cientifico), Jimenez Orozco, Encarnacion (Miembro del Comite Cientifico), et. al.:
Actualizacion. Manual de Competencias del Medico Especialista en Oncologia Radioterapica. Agencia de Calidad Sanitaria de Andalucia. 2010. ISBN 978-84-92466-58-0

Virizuela Echaburu, Juan Antonio (Miembro del Comite Cientifico), Alonso Redondo, Enrique (Miembro del Comite Cientifico), Bayo Lozano, Eloísa (Miembro del Comite Cientifico), Exposito Hernandez, Jose (Miembro del Comite Cientifico), Fernandez Lopez, Maria Auxiliadora (Miembro del Comite Cientifico), et. al.:
Manual de Competencias del /de la Medico/a Especialista en Oncologia Radioterapica. Agencia de Calidad Sanitaria de Andalucia. 2007. ISBN 978-84-96714-46-5

Capítulos en Libros
Salvador Bofill, Francisco Javier:
Epidemiología y Etiología. Atlas Integral de Cáncer de Mama. Pag. 2-7. En: Epidemiología y Etiología. Atlas Integral de Cáncer de Mama. You&US, S.A. 2010

Bernabé Caro, Reyes, Salvador Bofill, Francisco Javier:
Factores Predictivos de Respuesta a Inhibidores de Tirosincinasa en el Tratamiento del Cancer de Pulmon: Mutaciones, Expresion Egfr, Amplificacion, Otros. Pag. 287-296. En: Cancer de Pulmon. España. Just in Time, S.L. 2006

Bernabé Caro, Reyes, Fernandez Parra,Eva Maria, Salvador Bofill, Francisco Javier:
Diagnostico y Evolucion del Dolor Oncologico con Fentanilo TTS en la Practica Clinica. Pag. 37-42. En: Diagnostico y Evolucion del Dolor Oncologico con Fentanilo TTS en la Practica Clinica. Grupo Editorial Entheos. 2005. ISBN 84-934269-1-1

Publicaciones en Revistas
Salvador Bofill, Francisco Javier:
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. En: Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017. Vol. 19. Núm. 3. Pag. 341-356. 10.1007/s12094-016-1535-8

Salvador Bofill, Francisco Javier:
Articulo en prensa: Cost Minimization Analysis of Treatment With Intravenous or Subcutaneous Trastuzumab in Patients With Her2-Positive Breast Cancer in Spain. En: Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2017. 10.1007/s12094-017-1684-4

Salvador Bofill, Francisco Javier:
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. En: Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015. Vol. 17. Núm. 2. Pag. 160-166. 10.1007/s12094-014-1210-x

Salvador Bofill, Francisco Javier:
Bone turnover markers as predictive indicators of outcome in patients with breast and bone metastases treates with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study). En: Bone. 2014. Vol. 68. Núm. 68. Pag. 32-40

Salvador Bofill, Francisco Javier:
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. En: Journal of Clinical Oncology. 2013. Vol. 31. Núm. 20. Pag. 2593-2599. 10.1200/Jco.2012.46.9841

Salvador Bofill, Francisco Javier, Salvador Bofill, Francisco Javier, Grávalos, C, Albanell, Joan, Alba Conejo, Emilio:
Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. En: Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012. Vol. 14. Núm. 11. Pag. 820-826. 10.1007/s12094-012-0873-4

Salvador Bofill, Francisco Javier, Grávalos, C, Salvado Bofill, Francisco Javier, Albanell, Joan, Barnadas, a, et. al.:
Functions and workload of medical oncologists in Spain. En: Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012. Vol. 14. Núm. 6. Pag. 423-429

Salvador Bofill, Francisco Javier:
Meeting-Abstract: Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy. En: Breast Cancer Research. 2012. Vol. 13. Núm. 2. 10.1186/bcr3025

Calderón Montaño, José Manuel, Burgos Morón, Estefanía, Pérez Guerrero, Concepción, Salvador Bofill, Francisco Javier, Robles Frias, Antonio, et. al.:
Role of the Intracellular Ph in the Metabolic Switch Between Oxidative Phosphorylation and Aerobic Glycolysis - Relevance to Cancer. En: WebmedCentral. 2011. Vol. 2. Núm. 3

Fuentes Pradera, J., Salvador Bofill, Francisco Javier, Grilo Reina, A., Lopez Ladron, A., Bernabe Caro, R., et. al.:
Meeting-Abstract: Chronology of the Arterial Hypertension Associated With Inhibiting Treatments of Vascular Endothelium Growth Factor Receptor in Patients With Cancer. En: Journal of Clinical Oncology. 2010. Vol. 28. Núm. 15

Colomer, Ramon, Alba Conejo, Emilio, Paz Ares Rodriguez, Luis Gonzaga, Martin, M, Llombart, A., et. al.:
Treatment of Cancer With Oral Drugs: a Position Statement by the Spanish Society of Medical Oncology (Seom). En: Annals of oncology. 2010. Vol. 21. Núm. 2. Pag. 195-198

Burgos Morón, Estefanía, Calderón Montaño, José Manuel, Salvador Bofill, Francisco Javier, Robles Frias, Antonio, López Lázaro, Miguel:
The Dark Side of Curcumin. En: International Journal of Cancer. 2010. Vol. 126. Núm. 7. Pag. 1771-1775

Moreno Vega, Antonio, Chavarria, N, Rubio, J, Villandiego, I, Estepa, R, et. al.:
Meeting-Abstract: Primary Breast Sarcoma: Clinical and Retrospective Analysis of Cases from Jerez General Hospital, Spain. En: Journal of Clinical Oncology. 2009. Vol. 27. Núm. 15S

Salvador Bofill, Francisco Javier, Ruiz, M, Bayo, J, Lomas, M, Moreno, a, et. al.:
Meeting-Abstract: Multicenter Study of Weekly Trastuzumab, Paclitaxel, and Carboplatin Followed by a Week of Rest Every 28 Days in Patients With Her2+ Metastatic Breast Cancer. En: Journal of Clinical Oncology. 2008. Vol. 26. Núm. 15S. Pag. 1080-1080

Salvador Bofill, Francisco Javier, Ruiz Borrego, Manuel, Bayo Calero, Juan Lucas, Lomas, M, Moreno Vega, Antonio, et. al.:
Meeting-Abstract: Multicenter Study of Weekly Trastuzumab, Paclitaxel and Carboplatin Followed by a Week of Rest Every 28 Days in Patients With Her2+metastatic Breast Cancer - Incidence of Central Nervous System Metastases. En: European Journal Of Cancer. Supplement (1990). 2008. Vol. 6. Núm. 7. Pag. 172-173

Lomas Garrido, Maria de la Cabeza, Bayo, J, Lomas, M, Salvador Bofill, Francisco Javier, Moreno, a, et. al.:
A Multicentre Phase II Study to Evaluate Sequential Docetaxel Followed by Capecitabine Treatment in Anthracycline-Pretreated Her-2-Negative Patients With Metastatic Breast Cancer. En: Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2008. Vol. 10. Núm. 12. Pag. 817-825

Ruiz, M, Salvador Bofill, Francisco Javier, Bayo, J, Lomas, M, Moreno, A., et. al.:
Meeting-Abstract: Multicenter Study of Weekly Trastuzumab, Paclitaxel and Carboplatin Followed by a Week of Rest Every 28 Days in Patients With Her2+ Metastatic Breast Cancer (Mbc). En: Journal of Clinical Oncology. 2007. Vol. 25. Núm. 18. Pag. 1083-1083

Lomas, M, Salvador Bofill, Francisco Javier, Ruiz, M, Bayo, J:
Meeting-Abstract: Safety of Long-Term Administration of Capecitabine in Metastatic Breast Cancer. En: Journal of Clinical Oncology. 2006. Vol. 24. Núm. 18S. Pag. 10755-10755

Bayo, J, Lomas, M, Salvador Bofill, Francisco Javier, Ruiz, M, Moreno, A.:
Meeting-Abstract: Docetaxel (T) Followed by Capecitabine (X) As First-Line Chemotherapy in Patients (Pts) With Metastatic Breast Cancer (Mbc): Preliminary Findings from a Phase II Study. En: Journal of Clinical Oncology. 2006. Vol. 24. Núm. 18S. Pag. 10692-10692

Bayo, J, Salvador Bofill, Francisco Javier, Lomas, M, Ruiz, M, Baena, J., et. al.:
Meeting-Abstract: Docetaxel Followed by Capecitabine As First-Line Chemotherapy in Metastatic Breast Cancer Patients: Preliminary Results. En: Journal of Clinical Oncology. 2005. Vol. 23. Núm. 16S. Pag. 854-854

Bernabé Caro, Reyes, Salvador Bofill, Francisco Javier:
Tratamiento Quimioterápico Adyuvante y Neoadyuvante del Cáncer de Mama. En: Ciencia Ginecologika. 2004. Vol. 8. Núm. 2. Pag. 142-151

Vicente Baz, David, Mazo, Jose Maria, Salvador Bofill, Francisco Javier, Bernabé Caro, Reyes, Moreno Nogueira, Jose Andres:
Degeneración Cerebelosa Paraneoplásica y Carcinoma de Ovario. En: Oncología. 2001. Vol. 24. Núm. 8. Pag. 421-423

Salvador Bofill, Francisco Javier:
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

Aportaciones a Congresos
Salvador Bofill, Francisco Javier:
Magnetic resonance diffusion as predictive value of response to tratment with chemo-radiotherapy in patients with locally advanced rectal cancer. Poster en Congreso. European Society for medical Oncology. Madrid. 2014

Salvador Bofill, Francisco Javier:
Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625. Poster en Congreso. 2013 ASCO Annual Meeting. Chicago, Estados Unidos de América. 2013

Salvador Bofill, Francisco Javier:
Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC). Poster en Congreso. 2013 ASCO Annual Meeting. Chicago, Estados Unidos de América. 2013

Salvador Bofill, Francisco Javier:
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastasic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study. Poster en Congreso. 2012 ASCO Annual Meeting. Chicago. 2012

Ruiz Borrego, Manuel, Salvador Bofill, Francisco Javier, Valero Arbizu, María, Vicente Baz, David, Limon Miron, Maria Luisa, et. al.:
¿Cisplatino, gencitabina y lapatinib en pacientes con cáncer metastásico Her-2+. Experiencia en la práctica clínica¿. Comunicación en congreso. XII Congreso de la Sociedad Española de Oncología Médica, Málaga 2011. 2011

Salvador Bofill, Francisco Javier, Et Al., :
Phase II Open Label Trial Bevacizumab in Combination With Paclitaxel and Gemcitabine As First Line in Patients With Her-2 Negative Recurrent or Metastatic Breast Cancer (Avaluz): First Analysis. Poster en Congreso. 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, EEUU. 2010. 33rd Annual San Antonio Breast Cancer Symposium. P2-16-13. P2-16-13

Salvador Bofill, Francisco Javier:
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastasic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study. Poster en Congreso

Salvador Bofill, Francisco Javier:
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastasic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study. Poster en Congreso

Vicerrectorado de Investigación. Universidad de Sevilla. Pabellón de Brasil. Paseo de las Delicias s/n. Sevilla